Keep current on the latest news from Allegro Ophthalmics

Sign up today to be notified about the initiation of clinical trials, study results and breaking company news.

Your info will never be shared with a third-party

No Thanks

About Allegro

Loss of vision is a real risk for millions of people suffering from macular degeneration and diabetes. Doctors and patients need additional and more effective treatment options.

With over 100 years of combined experience, the seasoned leadership team at Allegro Ophthalmics is dedicated to establishing integrin peptide therapy as the next generation pharmaceutical category for the treatment of vitreoretinal diseases.

Currently in Phase 2 studies for multiple indications, Allegro’s lead investigational drug Luminate® has been shown to significantly reduce the current burden of intravitreal injections and to be a viable option for patients with wet age-related macular degeneration and diabetic macular edema.

By quickly, safely and cost-effectively bringing to market new and improved treatment options for leading causes of blindness, Allegro is committed to offering patients an improved quality of life by self-sufficient, functional vision.

We invite you to learn more about Allegro Ophthalmics and Luminate® for the treatment of vitreoretinal diseases.